University Health Network Joins Forces with Helix
In a remarkable new partnership, University Health Network's Princess Margaret Cancer Centre collaborates with Helix, a frontrunner in precision health, diving into one of the largest population genomics studies ever in the region. This initiative, known as the OurGenes Study, aims to enroll up to 100,000 people over a span of five years, focusing on elevating precision medicine and early detection of hereditary health risks.
Understanding Genetic Risks
Participants in the OurGenes Study will gain valuable insights into well-established genetic conditions like hereditary breast and ovarian cancer (BRCA1/2), Lynch Syndrome, and familial hypercholesterolemia. These conditions are known as Tier 1 genomic conditions by the CDC, illustrating their significance in clinical actionability and overall public health.
Proactive Health Management
The outcomes from genetic screenings will allow not just individuals but their healthcare teams to make informed choices regarding their health. This proactive approach might delay or even prevent occurrences of cancer and heart disease, addressing these critical health concerns effectively. By screening at a large scale, UHN will also be able to pinpoint health risks that might be affecting particular communities disproportionately.
Voices Behind the Project
Dr. Brad Wouters, UHN's Executive Vice President of Science and Research, emphasized the initiative's significance, stating, "UHN's mission is to transform lives and communities through excellence in care. This project empowers us to offer early genetic screening aids to participants in a personalized manner, improving health outcomes significantly." His enthusiasm reflects a broader commitment to moving beyond typical care protocols, striving to integrate advanced tools into everyday healthcare.
Impact on Families
Moreover, Dr. Keith Stewart, UHN's VP Cancer and Director at Princess Margaret, highlighted the importance of collecting extensive health data to identify families at heightened risk of severe diseases. He explained that doing so would facilitate comprehensive genetic counseling and more frequent screenings, ultimately allowing for possible interventions tailored to these high-risk individuals.
Sample Collection and Analysis
Under the guidance of Dr. Raymond Kim, participants' samples will undergo whole exome sequencing at Helix, an advanced method that thoroughly examines genetic codes to identify significant variations. Participants can expect results within eight to twelve weeks, along with access to genetic counseling and ongoing insights into their genomic health throughout their lives.
Addressing the Care Gap
Dr. James Lu, CEO of Helix, noted the alarming statistic that traditional care misses up to 90% of patients with serious disease risks. This partnership aims to bridge that gap, especially within the oncology population, leading toward improved diagnosis and better care. Helix’s Research Network, noted as one of the most rapidly expanding precision clinical research networks globally, will contribute significantly to this initiative.
Community Support
The OurGenes Study is supported by generous contributions to The Princess Margaret Cancer Foundation, underscoring the project’s community roots and collaborative essence. Participation is not only voluntary but also costs nothing to the participants, making it accessible to a broader audience.
About University Health Network
University Health Network (UHN) is recognized as Canada’s Hospital. It includes various facilities such as the Toronto General Hospital, Toronto Western Hospital, and Princess Margaret Cancer Centre, among others. With a team of over 44,000 professionals, UHN is renowned for its extensive medical research, particularly in diverse fields such as oncology, cardiology, and genomic medicine. UHN partners with the University of Toronto to continue pushing the boundaries of healthcare and education.
About Helix
Helix stands at the forefront of population genomics and precision health, facilitating healthcare systems and companies to seamlessly incorporate genomic data into patient care. This aims to accelerate therapeutic development, ensuring that each person receives tailored care based on their genetic background.
Frequently Asked Questions
What is the OurGenes Study?
The OurGenes Study is a partnership initiative focusing on enrolling up to 100,000 individuals to study hereditary health risks and improve precision medicine.
Who can participate in the OurGenes Study?
The study is open to eligible individuals interested in understanding their genetic health risks. Participation is voluntary and free of charge.
What types of conditions does the study address?
Participants will be tested for hereditary breast and ovarian cancer, Lynch Syndrome, and familial hypercholesterolemia, among others.
How will participants receive their results?
Results from the whole exome sequencing will be available to participants within eight to twelve weeks, along with genetic counseling options.
Why is this study important?
This study aims to enhance early detection and proactive healthcare for individuals, particularly those at higher risk for certain hereditary conditions.
